1-2 of 2 results for subject:Patients
Librarians' tools
- Search time
- 0.181 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Patients
- We searched for
- subject_t:Patients OR subject_t:"Sick people" OR subject_ses:92375
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, with reference to his Department’s consultation entitled Cost effectiveness methodology for vaccination programmes, published in February 2018, how many medicines and vaccines were approved for funding in England in each of the last five years with a cost per...
To ask the Secretary of State for Health and Social Care, with reference to his Department’s consultation entitled Cost effectiveness methodology for vaccination programmes, published in February 2018, how many medicines and vaccines were approved for funding in England in each of the last five years with a cost per...
In relation to vaccines approved for funding in each of the last five years, a cost per quality-adjusted life year threshold of £20,000 has been used not £15,000.
An assessment has been produced of the impact on the price that we would be willing to pay for existing vaccine programmes were we to adopt recommendations in the Cost Effectiveness Methodology for Immunisation Programmes and Procurement report that is currently out for consultation. One of these recommendations is to change the threshold from £20,000 to £15,000. This assessment is based on commercially confidential information, therefore the requested information cannot be provided.
The information requested in relation to medicines could only be obtained at disproportionate cost.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on (a) patients and (b) public health of reducing the cost per QALY threshold in England to £15,000 for medicines and vaccines; and if he will make a statement.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on (a) patients and (b) public health of reducing the cost per QALY threshold in England to £15,000 for medicines and vaccines; and if he will make a statement.
For vaccines, the Department is currently consulting on the Cost Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) report which was produced by the independent CEMIPP group. This is available at the following link:
The CEMIPP group was set up to look at the methodology for determining the cost-effectiveness of new and existing immunisation programmes and to make recommendations on if and how methodology could be improved. This report included a recommendation that the cost per quality-adjusted life year threshold for vaccines should change from £20,000 to £15,000.
An assessment of what impact this, and a number of other recommendations in the CEMIPP report, might have on the cost effectiveness of existing vaccination programmes has been produced. This is based on commercially confidential information.
In addition, the Department has considered the impact of changing the National Institute for Health and Care Excellence thresholds for medicines on patients. This is also based on commercially sensitive information.